Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of April 19, 2025, Neurogene (NGNE) has a market cap of $0.16 billion USD. According to our data, Neurogene is ranked No.7188 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Apr 19, 2025 | $0.16 B |
-51.74%
|
| Dec 31, 2024 | $0.34 B |
17.96%
|
| Dec 29, 2023 | $0.29 B |
90.37%
|
| Dec 30, 2022 | $0.15 B |
-89.44%
|
| Dec 31, 2021 | $1.43 B |
-65.82%
|
| Dec 31, 2020 | $4.19 B |
14.45%
|
| Dec 31, 2019 | $3.66 B |
470.37%
|
| Dec 31, 2018 | $0.64 B |
-81.63%
|
| Dec 29, 2017 | $3.49 B |
-28.77%
|
| Dec 30, 2016 | $4.91 B |
32.29%
|
| Dec 31, 2015 | $3.71 B |
66.40%
|
| Dec 31, 2014 | $2.23 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Biogen
BIIB
|
$17.36 B |
-0.001 M
|
USA
|
 Amgen
AMGN
|
$149.09 B |
0.124 B
|
USA
|
 Regeneron Pharmaceuticals
REGN
|
$61.57 B |
1.023 B
|
USA
|
 Gilead Sciences
GILD
|
$130.32 B |
-0.001 M
|
USA
|
 Vertex Pharmaceuticals
VRTX
|
$125.74 B |
-0.003 M
|
USA
|
 Eli Lilly
LLY
|
$754.27 B |
0.008 M
|
USA
|
 Pfizer
PFE
|
$125.57 B |
0.001 M
|
USA
|
 Johnson & Johnson
JNJ
|
$379.48 B |
-0.003 M
|
USA
|
 Merck
MRK
|
$196.28 B |
0.008 M
|
USA
|
 Novartis
NVS
|
$219.89 B |
0.932 B
|
Switzerland
|
 Sanofi
SNY
|
$124.64 B |
0.327 B
|
France
|
 AbbVie
ABBV
|
$306.02 B |
0.008 M
|
USA
|
 Bristol-Myers Squibb
BMY
|
$100.17 B |
-0.004 M
|
USA
|
 AstraZeneca
AZN
|
$210.29 B |
0.735 B
|
UK
|
| Market Cap | = | NGNE Stock Price | * | NGNE Shares Outstanding |
| = | $11.49 | * | 14.26 M | |
| = | $0.16 B |